贝利尤单抗治疗系统性红斑狼疮的研究进展  

Research progress of Beliumab in the treatment of systemic lupus erythema tosus

作　　者：廖玉芳 谢彤 LIAO Yufang;XIE Tong(Department of Rheumatology and Immunology,Affiliated Hospital of Guangdong Medical University,Zhanjiang Guangdong 524000)

机构地区：[1]广东医科大学附属医院风湿免疫科,广东湛江524000

出　　处：《当代医药论丛》2023年第15期13-16,共4页

摘　　要：系统性红斑狼疮(Systemic lupus erythematosus,SLE)是一种慢性多系统受累的自身免疫性疾病,其发病与B淋巴细胞的异常激活密切相关。贝利尤单抗(Belimumab)是一种全人源免疫球蛋白单克隆抗体,能与可溶性B淋巴细胞刺激因子(B-lymphocyte stimulator,BLyS)结合并抑制其生物活性,是近50多年来全球第一个获批专门用于治疗SLE的生物制剂。本文就贝利尤单抗的作用机理、随机对照研究、真实世界研究及安全性作一综述,以期为SLE患者的治疗提供参考依据。Systemic lupus erythematosus(SLE)is a chronic multisystem autoimmune disease,its pathogenesis is closely related to the abnormal activation of B lymphocytes.Belimumab is a fully human immunoglobulin monoclonal antibody,which can bind to soluble B-lymphocyte stimulator(BLyS)and inhibit its biological activity.Belimumab is the first biologic agent approved specifically for the treatment of SLE in the world in the past 50 years.This article reviews the mechanism of action,randomized controlled studies,real world studies and safety of Beliuzumab in order to provide reference for the treatment of SLE patients.

关 键 词：贝利尤单抗 系统性红斑狼疮 B淋巴细胞刺激因子 疗效 安全性 

分 类 号：R593.24[医药卫生—内科学]